Continuing Education Activity

Prolactin, a hormone exclusively synthesized and secreted by lactotrophs in the anterior pituitary gland, plays a vital role in reproductive physiology. Hyperprolactinemia, defined by serum prolactin levels exceeding 15 to 20 ng/mL, may arise from physiological, pathological, or drug-induced causes. This course reviews the clinical presentation of hyperprolactinemia, including reproductive dysfunction, galactorrhea, or symptoms of mass effect such as headache and visual field defects. Participants will gain an understanding of the evaluation, which involves serum prolactin measurement, exclusion of secondary causes, and pituitary imaging, as well as key diagnostic considerations, including the hook effect and macroprolactinemia. 

This course explores prolactin physiology, hyperprolactinemia evaluation, and evidence-based management, which depends on etiology and may involve thyroid replacement, medication adjustments, or dopamine agonists. Surgery or radiotherapy is reserved for resistant prolactinomas. The interpretation of laboratory and imaging findings, identification of diagnostic pitfalls, and application of appropriate therapeutic strategies are also discussed. This activity for healthcare professionals is designed to enhance the learner's competence in identifying hyperprolactinemia, performing the recommended evaluation, and implementing an appropriate interprofessional approach when managing this condition, ultimately optimizing outcomes for patients with prolactin disorders and patient-centered endocrine care.

Objectives:

• Identify the causes of hyperprolactinemia.
• Assess patients with suspected hyperprolactinemia using evidence-based diagnostic algorithms.
• Implement appropriate therapeutic interventions for hyperprolactinemia.
• Collaborate with interprofessional team members to ensure coordinated, patient-centered care and improve outcomes for patients affected by hyperprolactinemia.

Introduction

Prolactin hormone originates exclusively from lactotrophs located in the anterior pituitary gland, where it undergoes synthesis and secretion. The secretion rate ranges from 200 to 536 µg per day, with a half-life between 25 and 50 minutes.[1] Clearance of prolactin occurs primarily through the liver, accounting for approximately 75%, while the kidneys contribute to the remaining 25%. Basal prolactin levels average 13 ng/mL in women and 5 ng/mL in men.[1] Most laboratories define the upper normal limit of serum prolactin as 15 to 20 ng/mL. Serum prolactin concentrations exceeding this threshold indicate hyperprolactinemia. The underlying causes of hyperprolactinemia may be physiological, pathological, or drug-induced. Affected individuals may remain asymptomatic or present with manifestations, eg, hypogonadism and galactorrhea, depending on the degree and duration of hormonal elevation.

Etiology

Hyperprolactinemia can result from physiological, pathological, pharmacological, systemic, genetic, or ectopic factors.[2][3] Any condition that alters prolactin secretion or clearance can lead to elevated serum levels. Physiological hyperprolactinemia is typically transient and adaptive, whereas pathological and pharmacological causes often produce symptomatic elevations with potential long-term consequences.

Physiological Causes

Pregnancy, lactation, nipple stimulation, exercise, stress (including hypoglycemia, myocardial infarction, or surgery), seizures, sleep, the neonatal period, and sexual intercourse can all transiently elevate prolactin. During pregnancy, the pituitary gland enlarges, with lactotroph size increasing and overall gland size potentially doubling.[4] Serum prolactin rises throughout pregnancy, peaking at delivery due to elevated estradiol levels, and usually reaches 35 to 600 ng/mL at term.[5] Amniotic fluid prolactin levels may be 100 times higher than maternal or fetal serum.[5] 

Nipple stimulation increases prolactin secretion, which is mediated by neural pathways during breastfeeding. Prolactin secretion increases transiently with suckling, reaching levels of up to 300 ng/mL above baseline. Even with continued breastfeeding, the prolactin levels continue to decline.[6] The prolactin level can range from 30 to 300 ng/mL.

Pathological Causes

Pituitary disease

Pituitary disorders include:

• Prolactinoma 
• Acromegaly
• Cushing disease
• Macroadenoma (compressive)
• Plurihormonal adenoma (usually with concomitant growth hormone excess)
• Lymphocytic hypophysitis
• Parasellar mass
• Macroprolactinemia 

Prolactinomas, benign tumors of lactotrophs, account for up to 40% of pituitary adenomas and can present with any degree of elevated prolactin, from mild levels to 50,000 ng/mL. In contrast, prolactin elevation from other causes rarely exceeds 200 ng/mL.[7] 

Hypothalamic disease

Hypothalamic disorders, including injury to the stalk, that can lead to hyperprolactinemia include:

• Tumors like craniopharyngioma, suprasellar pituitary mass extension, meningioma, dysgerminoma, and hypothalamic metastases
• Granulomas (sarcoidosis, tuberculosis)
• Infiltrative disease (histiocytosis disease)
• Rathke cyst
• Pituitary stalk transection (Sellar surgery, head trauma)
• Skull base irradiation

Pharmacological Causes

Drugs influencing prolactin levels include estrogen therapy, thyrotropin-releasing hormone, dopamine receptor-blocking agents (eg, risperidone, haloperidol, fluphenazine), antiemetics (metoclopramide, domperidone, prochlorperazine), tricyclic antidepressants and selective serotonin reuptake inhibitors (eg, amitriptyline, clomipramine, fluoxetine), anticonvulsants (phenytoin), antihypertensives (verapamil, methyldopa, labetalol), H2 antihistamines (eg, cimetidine and ranitidine), opioid analgesics, and cholinergic agents (eg, physostigmine). Risperidone can produce the most significant elevations, sometimes exceeding 100 to 200 ng/mL, whereas atypical antipsychotics generally cause milder increases.

Systemic and Other Causes

Chronic renal failure, polycystic ovarian disease, liver cirrhosis, pseudocyesis, reflex etiologies (eg, chest wall trauma or surgery and herpes zoster), and primary hypothyroidism (via elevated TRH, which stimulates both prolactin and thyroid-stimulating hormone secretion) may elevate prolactin. Genetic inactivating prolactin receptor mutations, ectopic production by bronchogenic carcinoma or hypernephromas, and idiopathic causes represent additional sources of hyperprolactinemia.[8][9][8]

Epidemiology

Hyperprolactinemia occurs in less than 1% of the general population and 5% to 14% of patients presenting with secondary amenorrhea.[10] The most common type is a prolactin-secreting tumor (prolactinoma), accounting for up to 40% of all clinically recognized pituitary adenomas.[11] The mean prevalence of prolactinoma is estimated to be around 30 per 100,000 in women and 10 per 100,000 in men, with peak prevalence in women aged between 25 and  34.[11] Clinical manifestations in women are more pronounced and typically appear earlier than in men.

Pathophysiology

Structure and Regulation

Prolactin is a polypeptide hormone containing 199 amino acids.[12] The monomeric form weighs 23 kDa; this is the most biologically active form.[13] Prolactin also circulates in the blood in a dimeric form (weighs 48-56 kDa) and as macroprolactin (monomeric prolactin bound to immunoglobulin G). Marcoprolactin is biologically inactive.[14]

The prolactin gene expression is influenced by estrogen, dopamine, thyrotropin-releasing hormone, and oxytocin.[15] Other prolactin-releasing factors are a vasoactive intestinal peptide, endothelial growth factor, and dopamine antagonists.[15] Thyrotropin-releasing hormone (TRH) is a potent prolactin-releasing factor.[16] The hypothalamic control of prolactin secretion is primarily inhibitory, through dopamine activity. The tubuloinfundibular neurons in the hypothalamus are located in the arcuate neurons of the hypothalamus. These neurons release dopamine into the hypophyseal portal circulation, which then reaches the lactotrophs, causing tonic inhibition of prolactin release via the type 2 dopamine receptors on these cells.[17][18]

In primary hypothyroidism, TRH is elevated, which increases both TSH and prolactin levels. Furthermore, up to 20% to 40% of patients with hypothyroidism have hyperprolactinemia, depending on the severity of thyroid hormone deficiency.[19][20] Drugs like neuroleptics elevate prolactin because of their dopamine receptor antagonist property, and atypical antipsychotics act by antagonizing the secretion of serotonin and dopamine. Pituitary or sellar tumors inhibit dopamine-induced hyperprolactinemia because of pressure on the pituitary stalk or interruption of the vascular connections between the pituitary and hypothalamus.

Role of Prolactin

Prolactin is responsible for milk production during pregnancy and lactation. Along with estrogen, progesterone, and possibly insulin-like growth factor-1 (IGF-1), prolactin stimulates breast alveolar element proliferation during pregnancy.[21] Lactation is suppressed during pregnancy due to the high level of estrogen.[22] Active lactation occurs due to decreased estrogen and progesterone levels, accompanied by an increase in prolactin levels, following delivery. During pregnancy, estrogen has a stimulatory effect on the proliferation of lactotrophs, which in turn secrete prolactin. Lactation results in amenorrhea and secondary infertility because of prolactin-mediated suppression of gonadotropins.

Prolactin inhibits the release of gonadotropin-releasing hormone, leading to a reduction in the secretion of luteinizing hormone and follicle-stimulating hormone.[23][24] Symptoms of hypogonadism depend upon the magnitude of prolactin elevation. Serum prolactin greater than 100 ng/mL will have overt hypogonadism with the presentation of amenorrhea, hot flashes, and vaginal dryness. Serum prolactin levels between 50 and 100 ng/mL may cause amenorrhea or oligomenorrhea, while levels of 20 to 50 ng/mL may only shorten the luteal phase due to insufficient progesterone secretion.[25][26]

Prolactin has a significant impact throughout the body, affecting metabolic hemostasis, immunoregulation, and osmoregulation.[27][28][29] In the central nervous system, it influences neurogenesis, neurodevelopment, neuroprotection, behavior, sleep, learning, and even memory.[30][31][32]

History and Physical

Clinical Features of Hyperprolactinemia

Symptoms of hyperprolactinemia may arise from the direct effects of elevated prolactin or from compression caused by a structural lesion in the pituitary region. Typical manifestations occur in premenopausal women and men but are uncommon in postmenopausal women.[33] Reproductive dysfunction and galactorrhea represent hallmark features of hyperprolactinemia. However, in children and adolescents, hyperprolactinemia can lead to growth arrest, delayed puberty, and primary amenorrhea.[34]

In females, clinical manifestations of hyperprolactinemia include:

• Menstrual disturbance (eg, oligomenorrhea, amenorrhea, menorrhagia, or infertility) 
• Galactorrhea (although most women who have hyperprolactinemia may not have galactorrhea, which happens in one-third to half of women) [35]
• Low bone mass [22]

In males, clinical manifestations of hyperprolactinemia include:

• Hypogonadotropic hypogonadism, including decreased libido, impotence, infertility, oligospermia, or gynecomastia [36]
• Erectile dysfunction
• Galactorrhea (rare, due to lower responsiveness of the breast tissue to prolactin)
• Low bone mass [22]

Clinical features caused by mass effects include:

• Headache
• Visual field defect
• External ophthalmoplegia

Evaluation

The clinician begins the evaluation of suspected hyperprolactinemia by measuring the serum prolactin level, ideally with a fasting sample taken mid-morning. An increase in prolactin secretion is associated with sleep. However, this increase is not part of the circadian rhythm. The peak level of prolactin typically occurs between 4 AM and 7 AM; therefore, the ideal time to measure prolactin is during the mid-morning hours, preferably in a fasting state..[37]  Food has a minimal effect on the serum concentration of prolactin. Therefore, fasting is not always a necessary condition for measuring serum prolactin levels, except when a mild elevation in the initial value is noted.[38]

If serum prolactin is elevated, the next step is to determine the cause in the following order:

1. Exclusion of physiological causes
2. Exclusion of pharmacological causes
3. Neuroradiological imaging of the hypothalamic-pituitary region

An extensive history and physical examination are crucial for excluding causes of hyperprolactinemia and inquiring about signs and symptoms associated with this condition.

Laboratory Tests

The following tests are generally needed depending upon gender, age, and clinical presentation:

• In a premenopausal female, an initial pregnancy test is essential.
• In case of mild prolactin elevation, repeating a serum prolactin level is recommended, as levels can often normalize, in which case further testing (especially in an asymptomatic individual) is unnecessary.
• Assessing thyroid function is essential to rule out underlying hypothyroidism, as correcting hypothyroid disfunctions with thyroid hormone replacement results in normalized prolactin levels.
• Renal function and liver function testing can be performed in select patients.
• If a pituitary adenoma is identified, other anterior pituitary hormones need to be evaluated, including: 

  • Insulin-like growth factor-1 (IGF-1)
  • Adrenocorticotropic hormone (ACTH)
  • Luteinizing hormone 
  • Follicle-stimulating hormone 
  • Free thyroxine (T4)
  • Testosterone or estradiol

Additional Diagnostic Studies

Magnetic resonance imaging (MRI) of the pituitary with contrast is the preferred imaging study. Additionally, visual field testing should be performed in cases of macroadenoma and tumors that are adjacent to or compressing the optic chiasm.

Diagnostic Pitfalls

Hook effect

The hook effect results from an artifact in the immunoradiometric assay that produces a falsely low prolactin concentration. This phenomenon should be suspected in patients with large pituitary adenomas showing only mild or moderate prolactin elevation. Extremely high serum prolactin concentrations can saturate both the capture and tracer antibodies used in the assay, preventing proper antibody–antigen complex formation and causing an erroneously low result. Repeating the measurement using a 1:100 serum dilution corrects this interference. Although uncommon, this artifact can lead to significant diagnostic errors if unrecognized.

Macroprolactin

Macroprolactin represents large circulating aggregates of prolactin and antibodies, with a size of approximately 150 kD; in contrast, native prolactin in serum is approximately 23 kD.[39] These aggregates are measurable in standard assays but possess minimal or no biological activity. Misinterpretation of such results can lead to a false diagnosis of prolactin hypersecretion.[40] Clinicians can prevent this error by treating serum samples with polyethylene glycol before testing, which precipitates macroprolactin and allows accurate measurement of biologically active prolactin.

Treatment / Management

Etiology-Specific Management

Treatment of hyperprolactinemia depends on the underlying cause. After physiological causes have been excluded, clinicians should evaluate for systemic, pharmacologic, or structural etiologies and address them appropriately in symptomatic individuals.

Hypothyroidism

The patient should be treated with thyroid replacement therapy, and the normalization of prolactin level should be confirmed after treatment.

Drug-induced hyperprolactinemia

Intervention becomes necessary only when patients develop hypogonadism, osteoporosis, or distressing galactorrhea.[41] When medications are suspected as the cause, temporary discontinuation is recommended, if feasible, to evaluate prolactin normalization. If discontinuation is not possible, particularly with antipsychotics, substitution with an alternative agent that does not elevate prolactin (eg, quetiapine) should be considered. When medication changes cannot be implemented, adding a dopamine agonist may provide benefit. Any medication adjustments must be made collaboratively with a psychiatrist.

Supplemental estradiol for women and testosterone for men may be appropriate to manage hypogonadism and low bone mass. If prolactin levels remain elevated after medication withdrawal or when discontinuation is not feasible, pituitary MRI should be performed to exclude an underlying adenoma. Risperidone requires special consideration, as it can produce marked prolactin elevations exceeding 200 ng/mL, whereas other psychotropic agents typically cause mild increases below 100 ng/mL.[42]

Hypothalamic disease

Removal of the pathologic cause is preferred; otherwise, hyperprolactinemia should be treated with a dopamine agonist.

Idiopathic hyperprolactinemia

Idiopathic hyperprolactinemia is treated with a dopamine agonist in symptomatic individuals.[43] However, these patients are relatively resistant to dopamine agonists. Dosage can be adjusted to maintain the lowest possible dose while achieving a normal level of prolactin. If the patient attains normal prolactin on the lowest dose of a dopamine agonist for 2 years, the drug can be discontinued as a trial.

Macroprolactinemia

In cases of macroprolactinemia, treatment is not required.

Prolactinoma

Treatment of prolactinomas involves medical, surgical, and radiation treatment approaches.

Medical therapy

The Endocrine Society guideline recommends against treatment with a dopamine agonist for asymptomatic microadenoma but recommends dopamine agonist therapy to decrease prolactin levels, tumor size, and normalize gonadal function for symptomatic patients with microadenomas or macroadenomas. Cabergoline is preferred to other dopamine agonists due to its higher efficacy in normalizing prolactin levels and tumor shrinkage.[44]

Cabergoline and bromocriptine are commonly used dopamine agonists. Quinagolide is not available in the United States but is used in some other countries. Pergolide had been withdrawn from the United States because of concerns about valvular heart disease. Cabergoline is the first choice because of its efficacy and fewer adverse effects.[22] Bromocriptine is preferred during pregnancy because of more favorable data than cabergoline.[11] Cabergoline has a longer duration of action than bromocriptine and is administered once or twice a week. Bromocriptine is administered once daily. Common adverse effects are nausea, vomiting, nasal stiffness, digital vasospasm, depression, and postural hypotension. High doses of dopamine agonists are associated with a risk of heart valve regurgitation.[45] Dopamine agonist therapy can be tapered and discontinued after 2 years of continuous treatment if the serum prolactin level is normal and no adenoma is visible in magnetic resonance imaging (MRI).[43]

Surgery and radiation therapies

Most prolactinomas are treated with medical therapy alone, with surgery and radiotherapy reserved for those who are resistant to medical treatment with the dopamine agonists. Endoscopic endonasal transsphenoidal surgery is the preferred surgical method. Prophylactic surgery is considered in women with large prolactinomas that potentially threaten vision during pregnancy.[46] Adjuvant radiation therapy should be regarded as for the residual tumor. Gamma knife stereotactic radiosurgery is often effective in treating prolactinomas resistant to or intolerant of dopamine agonists.[47]

Differential Diagnosis

Excluding potential underlying etiologies of hyperprolactinemia, primarily hypothyroidism and the use of drugs that inhibit dopamine, is essential in patients presenting with characteristic clinical features. Other differential diagnoses that should be considered include:

• Cirrhosis
• Dopamine antagonist medications
• Hypothalamic disease
• Idiopathic hyperprolactinemia
• Pituitary tumors
• Pregnancy
• Primary hypothyroidism
• Prolactinoma
• Renal failure

Prognosis

Most patients with microprolactinomas have a favorable prognosis and typically normalize their prolactin levels with treatment. These patients can be managed with medical therapy for a prolonged period. The success of pituitary surgery also depends on the size of the tumor, the serum prolactin level, and the neurosurgeon's experience and expertise. The success rate of pituitary surgery is related inversely to tumor size and prolactin levels.[48] 

Although microprolactinoma surgery has a high success rate, the recurrence of hyperprolactinemia is relatively high, which is about 17% in patients initially considered cured.[49] In the case of macroprolactinoma, approximately 50% of patients are in remission after surgery. For invasive tumors, complete resection may not be possible, and prolactin normalizes in only 32% of patients with a recurrence rate of about 19%.

Complications

Complications of hyperprolactinemia include:

• Hypogonadism
• Infertility
• Osteoporosis
• Mass effects leading to visual deficits, cranial nerve palsies, pituitary apoplexy, cerebrospinal fluid leak, and hypopituitarism

Consultations

Consultation with the following interprofessional specialties may be involved in the management of hyperprolactinemia:

• Endocrinology
• Gynecology
• Neurosurgery
• Psychiatry
• Radiation oncology

Deterrence and Patient Education

Deterrence and patient education play a critical role in the management of hyperprolactinemia, particularly in preventing unnecessary diagnostic procedures, medication-induced recurrence, and complications related to untreated disease. Clinicians should emphasize the importance of adherence to prescribed therapies, including thyroid hormone replacement in hypothyroid patients and dopamine agonists for prolactinomas. Patients using medications known to increase prolactin, eg, antipsychotics or antiemetics, should receive counseling on potential endocrine effects and the need for periodic prolactin monitoring. Coordination between psychiatry and endocrinology ensures that necessary psychotropic therapy continues while minimizing hormonal adverse effects. Education should also address the potential long-term impact of chronic hyperprolactinemia, including infertility, decreased libido, osteoporosis, and visual disturbances from tumor growth.

Patients should be advised to report symptoms, including menstrual irregularities, galactorrhea, erectile dysfunction, or vision changes, promptly. Those receiving dopamine agonists should understand potential adverse effects, including nausea, dizziness, and orthostatic hypotension, and the importance of gradual dose adjustment. Ongoing follow-up with prolactin level monitoring and periodic pituitary imaging helps detect recurrence or treatment resistance early. In addition, education regarding lifestyle modifications, eg, adequate calcium and vitamin D intake, weight-bearing exercise, and smoking cessation, can help preserve bone density and mitigate long-term skeletal complications. Empowering patients with knowledge about their condition and its management fosters adherence, reduces anxiety, and supports collaborative, patient-centered endocrine care.

Enhancing Healthcare Team Outcomes

Hyperprolactinemia refers to an elevated serum prolactin concentration resulting from physiological, pathological, or drug-induced causes. Common etiologies include pituitary adenomas (prolactinomas), hypothyroidism, and dopamine antagonist medications. Symptoms vary from asymptomatic cases to reproductive dysfunction, galactorrhea, and hypogonadism. Diagnosis requires exclusion of secondary causes, followed by appropriate imaging and laboratory testing. Management focuses on addressing the underlying cause, including pharmacologic therapy with dopamine agonists, thyroid hormone replacement, or surgical and radiologic interventions for macroadenomas. Early recognition and coordinated interprofessional care optimize outcomes and prevent complications, eg, infertility and osteoporosis.

Optimal management of hyperprolactinemia relies on effective collaboration among endocrinologists, general practitioners, advanced practitioners, nurses, pharmacists, and other specialists. Endocrinologists lead diagnostic evaluation and treatment planning, while primary care clinicians facilitate early detection and ensure continuity of care. Psychiatrists collaborate when antipsychotic medications contribute to elevated prolactin levels, and neurosurgeons become involved in cases of macroadenomas requiring surgical management. Pharmacists monitor drug efficacy, adverse effects, and interactions, ensuring appropriate therapy selection and patient adherence. Oncology nurses contribute by educating patients about potential radiation therapy and monitoring for hypopituitarism after treatment.[50][51] Through consistent communication, shared decision-making, and patient education, interprofessional teams enhance safety, adherence, and overall patient-centered outcomes in hyperprolactinemia management.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Melmed S. Pituitary-Tumor Endocrinopathies. N Engl J Med. 2020 Mar 05;382(10):937-950. [PubMed: 32130815]

2.

Chahal J, Schlechte J. Hyperprolactinemia. Pituitary. 2008;11(2):141-6. [PubMed: 18404389]

3.

Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am. 1992 Dec;21(4):877-901. [PubMed: 1486880]

4.

Scheithauer BW, Sano T, Kovacs KT, Young WF, Ryan N, Randall RV. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc. 1990 Apr;65(4):461-74. [PubMed: 2159093]

5.

Tyson JE, Hwang P, Guyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol. 1972 May 01;113(1):14-20. [PubMed: 5024994]

6.

Cox DB, Owens RA, Hartmann PE. Blood and milk prolactin and the rate of milk synthesis in women. Exp Physiol. 1996 Nov;81(6):1007-20. [PubMed: 8960706]

7.

Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977 Mar 17;296(11):589-600. [PubMed: 840242]

8.

Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, Drummond RS, van der Merwe PA, Klenerman P, Bountra C, Thakker RV. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med. 2013 Nov 21;369(21):2012-2020. [PMC free article: PMC4209110] [PubMed: 24195502]

9.

Turkington RW. Ectopic production of prolactin. N Engl J Med. 1971 Dec 23;285(26):1455-8. [PubMed: 5166245]

10.

Lee DY, Oh YK, Yoon BK, Choi D. Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. Am J Obstet Gynecol. 2012 Mar;206(3):213.e1-5. [PubMed: 22244474]

11.

Yatavelli RKR, Bhusal K. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 31, 2023. Prolactinoma. [PubMed: 29083585]

12.

Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev. 1995 Jun;16(3):354-69. [PubMed: 7671851]

13.

Bernard V, Young J, Chanson P, Binart N. New insights in prolactin: pathological implications. Nat Rev Endocrinol. 2015 May;11(5):265-75. [PubMed: 25781857]

14.

Kasum M, Pavičić-Baldani D, Stanić P, Orešković S, Sarić JM, Blajić J, Juras J. Importance of macroprolactinemia in hyperprolactinemia. Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:28-32. [PubMed: 25461348]

15.

Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000 Oct;80(4):1523-631. [PubMed: 11015620]

16.

Kanasaki H, Oride A, Mijiddorj T, Kyo S. Role of thyrotropin-releasing hormone in prolactin-producing cell models. Neuropeptides. 2015 Dec;54:73-7. [PubMed: 26297348]

17.

Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 1997 Dec 01;16(23):6926-35. [PMC free article: PMC1170296] [PubMed: 9384572]

18.

Qi-Lytle X, Sayers S, Wagner EJ. Current Review of the Function and Regulation of Tuberoinfundibular Dopamine Neurons. Int J Mol Sci. 2023 Dec 21;25(1) [PMC free article: PMC10778701] [PubMed: 38203281]

19.

Sharma LK, Sharma N, Gadpayle AK, Dutta D. Prevalence and predictors of hyperprolactinemia in subclinical hypothyroidism. Eur J Intern Med. 2016 Nov;35:106-110. [PubMed: 27473607]

20.

Hekimsoy Z, Kafesçiler S, Güçlü F, Ozmen B. The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism. Endocr J. 2010;57(12):1011-5. [PubMed: 20938100]

21.

Richert MM, Wood TL. The insulin-like growth factors (IGF) and IGF type I receptor during postnatal growth of the murine mammary gland: sites of messenger ribonucleic acid expression and potential functions. Endocrinology. 1999 Jan;140(1):454-61. [PubMed: 9886857]

22.

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA., Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. [PubMed: 21296991]

23.

Milenković L, D'Angelo G, Kelly PA, Weiner RI. Inhibition of gonadotropin hormone-releasing hormone release by prolactin from GT1 neuronal cell lines through prolactin receptors. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1244-7. [PMC free article: PMC43133] [PubMed: 8108395]

24.

Haidenberg-David F, Sidauy-Adissi J, Moscona-Nissan A, Jonguitud-Zumaya E, Fugarolas-Morinelli M, Martinez-Mendoza F, Taniguchi-Ponciano K, Marrero-Rodríguez D, Mercado M. Overview of Hyperprolactinemia: General Approach and Reproductive Health Implications. Arch Med Res. 2024 Dec;55(8):103102. [PubMed: 39454469]

25.

Seppälä M, Ranta T, Hirvonen E. Hyperprolactinaemia and luteal insufficiency. Lancet. 1976 Jan 31;1(7953):229-30. [PubMed: 55535]

26.

Corenblum B, Pairaudeau N, Shewchuk AB. Prolactin hypersecretion and short luteal phase defects. Obstet Gynecol. 1976 Apr;47(4):486-8. [PubMed: 943740]

27.

Legorreta-Haquet MV, Santana-Sánchez P, Chávez-Sánchez L, Chávez-Rueda AK. The effect of prolactin on immune cell subsets involved in SLE pathogenesis. Front Immunol. 2022;13:1016427. [PMC free article: PMC9650038] [PubMed: 36389803]

28.

Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and autoimmunity: The hormone as an inflammatory cytokine. Best Pract Res Clin Endocrinol Metab. 2019 Dec;33(6):101324. [PubMed: 31564625]

29.

Bernard V, Young J, Binart N. Prolactin - a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019 Jun;15(6):356-365. [PubMed: 30899100]

30.

Ramos-Martinez E, Ramos-Martínez I, Molina-Salinas G, Zepeda-Ruiz WA, Cerbon M. The role of prolactin in central nervous system inflammation. Rev Neurosci. 2021 Apr 27;32(3):323-340. [PubMed: 33661585]

31.

Bridges RS, Grattan DR. 30 years after: CNS actions of prolactin: Sources, mechanisms and physiological significance. J Neuroendocrinol. 2019 Mar;31(3):e12669. [PubMed: 30549349]

32.

Cabrera-Reyes EA, Limón-Morales O, Rivero-Segura NA, Camacho-Arroyo I, Cerbón M. Prolactin function and putative expression in the brain. Endocrine. 2017 Aug;57(2):199-213. [PubMed: 28634745]

33.

Pekić S, Medic Stojanoska M, Popovic V. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management. Neuroendocrinology. 2019;109(1):28-33. [PubMed: 30347396]

34.

Catli G, Abaci A, Altincik A, Demir K, Can S, Buyukgebiz A, Bober E. Hyperprolactinemia in children: clinical features and long-term results. J Pediatr Endocrinol Metab. 2012;25(11-12):1123-8. [PubMed: 23329759]

35.

Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Current evaluation of amenorrhea: a committee opinion. Fertil Steril. 2024 Jul;122(1):52-61. [PubMed: 38456861]

36.

Ciccarelli A, Guerra E, De Rosa M, Milone F, Zarrilli S, Lombardi G, Colao A. PRL secreting adenomas in male patients. Pituitary. 2005;8(1):39-42. [PubMed: 16411067]

37.

Spiegel K, Weibel L, Gronfier C, Brandenberger G, Follenius M. Twenty-four-hour prolactin profiles in night workers. Chronobiol Int. 1996 Oct;13(4):283-93. [PubMed: 8889252]

38.

Cienfuegos S, Corapi S, Gabel K, Ezpeleta M, Kalam F, Lin S, Pavlou V, Varady KA. Effect of Intermittent Fasting on Reproductive Hormone Levels in Females and Males: A Review of Human Trials. Nutrients. 2022 Jun 03;14(11) [PMC free article: PMC9182756] [PubMed: 35684143]

39.

Kavanagh-Wright L, Smith TP, Gibney J, McKenna TJ. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol (Oxf). 2009 Apr;70(4):599-605. [PubMed: 18771565]

40.

Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf). 2005 Jun;62(6):633-43. [PubMed: 15943822]

41.

Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004 Dec;65(12):1607-18; quiz 1590, 1760-1. [PubMed: 15641865]

42.

Stojkovic M, Radmanovic B, Jovanovic M, Janjic V, Muric N, Ristic DI. Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies. Front Psychiatry. 2022;13:874705. [PMC free article: PMC9121093] [PubMed: 35599770]

43.

Tritos NA, Miller KK. Diagnosis and Management of Pituitary Adenomas: A Review. JAMA. 2023 Apr 25;329(16):1386-1398. [PubMed: 37097352]

44.

Fachi MM, de Deus Bueno L, de Oliveira DC, da Silva LL, Bonetti AF. Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta-analysis. J Clin Pharm Ther. 2021 Dec;46(6):1549-1556. [PubMed: 34137053]

45.

Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826-9. [PubMed: 17706566]

46.

Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med. 1985 May 23;312(21):1364-70. [PubMed: 3887166]

47.

Liu X, Kano H, Kondziolka D, Park KJ, Iyer A, Shin S, Niranjan A, Flickinger JC, Lunsford LD. Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. Pituitary. 2013 Mar;16(1):68-75. [PubMed: 22302560]

48.

Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery. 1999 Feb;44(2):254-61; discussion 261-3. [PubMed: 9932878]

49.

Serri O, Rasio E, Beauregard H, Hardy J, Somma M. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983 Aug 04;309(5):280-3. [PubMed: 6866052]

50.

Langlois F, McCartney S, Fleseriu M. Recent Progress in the Medical Therapy of Pituitary Tumors. Endocrinol Metab (Seoul). 2017 Jun;32(2):162-170. [PMC free article: PMC5503860] [PubMed: 28685507]

51.

Cuny T, Barlier A, Feelders R, Weryha G, Hofland LJ, Ferone D, Gatto F. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives. Ann Endocrinol (Paris). 2015 Feb;76(1):43-58. [PubMed: 25556152]

Disclosure: Jasleen Kaur declares no relevant financial relationships with ineligible companies.

Disclosure: Kamal Bhusal declares no relevant financial relationships with ineligible companies.